Prestige BioPharma inks two new deals for its biosimilar trastuzumab
Category: #health  By Mateen Dalal  Date: 2019-07-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Prestige BioPharma inks two new deals for its biosimilar trastuzumab
  • The company would be able to supply and commercialize its biosimilar across Russia under the latest of the two deals.
     
  • The second deal, meanwhile, gives Prestige access to certain parts of Europe.

Prestige BioPharma (Prestige), a renowned Singapore-based biopharmaceutical company, has reportedly announced that it has signed two new agreements that would allow it to supply and commercialize its biosimilar trastuzumab, HD201, across Russia and parts of Europe.

Reports cite, the company signed the latest of the two deals with Pharmapark LLC, a private Russian pharmaceutical firm that is marketing five biosimilars across Russia at present. Meanwhile, the company inked the second deal with Mundipharma, a UK-based pharmaceutical company.

According to reports, the Mundipharma agreement would give the trastuzumab biosimilar access across a number of European countries including Spain, France, Sweden, Norway, Finland, Denmark, Austria, Switzerland and Portugal following the drug’s approval by the European Commission.

The CEO of Prestige BioPharma, Lisa S. Park, PhD, stated that the company is thrilled to collaborate with Mundipharma to commercialize its leading biosimilar across select European markets. Park further added that the proposed partnership is a crucial milestone for Prestige as it will boost the global availability of trastuzumab and benefit more patients through its accessibility and quality.

The new deals reportedly come as the latest in a string of agreements concerning the biosimilar for the Singapore-based biopharma company; in the fourth quarter of 2018, Prestige inked a licensing agreement with Cipla Limited to supply and commercialize trastuzumab across emerging markets. Earlier, the company also announced a deal with Alvogen to distribute the biosimilar across Eastern and Central Europe.

Sources familiar with the matter claim that the proposed biosimilar is currently being reviewed by the European Medicines Agency. Moreover, the company also plans to submit an application for the biosimilar with the U.S. FDA by the end of 2019.

Source Credits:

https://www.centerforbiosimilars.com/news/prestige-biopharma-strikes-2-more-deals-for-biosimilar-trastuzumab-hd201

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Stocks of luxury fashion houses raise in response to China’s reopening
Stocks of luxury fashion houses raise in response to China’s reopening
By Mateen Dalal

Luxury fashion houses dependent on Chinese customers reportedly saw a hike in stocks as China reopens, however, those clients may not necessarily be purchasing the goods elsewhere. In the past, wealthy Chinese customers would frequently buy person...

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...